Advertisement
Advertisement
AKTS
Aktis Oncology, Inc. Common stock
19.12
USDSponsored
+0.09
+0.47%
May 21, 16:00 UTC -4
Closed
After-Market
19.14
+0.02
+0.10%
AKTS Earnings Reports
Positive Surprise Ratio
AKTS beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Aktis Oncology, Inc. Common stock earnings per share and revenue
On May 11, 2026, AKTS reported earnings of -0.38 USD per share (EPS) for Q1 26, missing the estimate of -0.34 USD, resulting in a -11.54% surprise. Revenue reached 3.23 million, compared to an expected 1.78 million, with a 80.78% difference. The market reacted with a +7.99% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Aktis Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Aktis Oncology, Inc. Common stock reported EPS of -$0.38, missing estimates by -11.54%, and revenue of $3.23M, 80.78% above expectations.
How did the market react to Aktis Oncology, Inc. Common stock's Q1 2026 earnings?
The stock price moved up 7.99%, changed from $18.27 before the earnings release to $19.73 the day after.
When is Aktis Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Aktis Oncology, Inc. Common stock's next earnings report?
Based on --
analysts, Aktis Oncology, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement